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Abstract
The inhibition of the functions of c-Myc (endogenous and oncogenic) was recently shown to provide a spectacular
therapeutic index in cancer mouse models, with complete tumor regression and minimal side-effects in normal tissues. This
was achieved by the systemic and conditional expression of omomyc, the cDNA of a designed mutant of the b-HLH-LZ of c-
Myc named Omomyc. The overall mode of action of Omomyc consists in the sequestration of Max and the concomitant
competition of the Omomyc/Max complex with the endogenous c-Myc/Max heterodimer. This leads to the inhibition of the
transactivation of Myc target genes involved in proliferation and metabolism. While this body of work has provided
extraordinary insights to guide the future development of new cancer therapies that target c-Myc, Omomyc itself is not a
therapeutic agent. In this context, we sought to exploit the use of a b-HLH-LZ to inhibit c-Myc in a cancer cell line in a more
direct fashion. We demonstrate that the b-HLH-LZ domain of Max (Max*) behaves as a bona fide protein transduction
domain (PTD) that can efficiently transduce across cellular membrane via through endocytosis and translocate to the
nucleus. In addition, we show that the treatment of HeLa cells with Max* leads to a reduction of metabolism and
proliferation rate. Accordingly, we observe a decrease of the population of HeLa cells in S phase, an accumulation in G1/G0
and the induction of apoptosis. In agreement with these phenotypic changes, we show by q-RT-PCR that the treatment of
HeLa cells with Max* leads to the activation of the transcription c-Myc repressed genes as well as the repression of the
expression of c-Myc activated genes. In addition to the novel discovery that the Max b-HLH-LZ is a PTD, our findings open
up new avenues and strategies for the direct inhibition of c-Myc with b-HLH-LZ analogs.
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Introduction
c-Myc and Max are members of a large network of basic region-
Helix-Loop-Helix-Leucine Zipper (b-HLH-LZ) transcription fac-
tors. This network also includes L-Myc, N-Myc and the proteins
from the Mad family (Mad1, Mxi1, Mad3 and Mad4). The Myc
and the Mad proteins exert their transcriptional activities as Myc/
Max and Mad/Max heterodimers [1],[2],[3],[4],[5],[6],[7]. Max
is the only protein in the network able to homodimerize. It is the
HLH-LZ domains that are responsible for the homodimerization
of Max and the specific heterodimerization with Myc and Mad
proteins, while the basic regions mediate the specific DNA binding
[4–9]. All the dimers of this network bind a specific DNA sequence
called the consensus E-Box (CANNTG) located in the promoters
of c-Myc target genes [4],[5],[6],[7],[8],[9]. Once bound to the E-
Boxes at core promoters, c-Myc recruits, through its transactiva-
tion domain (TAD), co-activators (TRAPP and GCN5) with
Histone Acetyl Transferase (HAT) activities. While Max does not
possess a specialized domain capable of recruiting co-repressors, its
overexpression has been shown to inhibit c-Myc induced
proliferation through the competition for E-box sequence at target
gene promoters [10], [11]. Accordingly, the overexpression of
Max was shown not to be oncogenic because of the high levels of
expression compared to those of c-Myc [11].
The most recent estimates indicate that c-Myc regulates (up and
down) the transcription of up to 15% of the genome [12],[13].
Genes that are activated are generally involved in the cell cycle
progression (proliferation) and metabolism (growth), whereas the
list of repressed genes contains cell cycle inhibitors. Indeed, c-Myc
activates genes such CDKs and cyclins, ribosomal RNAs and
proteins implicated in the ribosomal genesis (e.g. nucleolin).
p15Ink4b, p21cip1 and p27kip1 are amongst the key repressed
genes.
In comparison to the mechanism of transactivation, the mode of
repression by c-Myc is less well understood [14]. It has been
demonstrated that c-Myc, as a heterodimer with Max, cooperates
with Miz1 to repress transcription of cell cycle inhibitors such as
p15, p21 and p27 [2],[4],[15],[16],[17],[18],[19],[20]. The
recruitment of c-Myc to the p15 and p21 core promoters is
thought to be solely dependent on DNA bound Miz1
[15],[16],[17]. However, it has been recently reported that direct
binding to E-box sequences located at repressed promoters also
contributes to the repression mechanism of p15 and p21. Since
Max does not interact with Miz1, it is possible that the anti-
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the activation of the transcription of cell cycle inhibitors and the
repression of the transcription of pro-proliferative genes.
c-Myc is overexpressed in the majority of malignancies, and
while its role in the tumorigenesis of these lesions has been clearly
established, the pertinence of targeting c-Myc as a therapeutic
treatment has been debated. Indeed, because c-Myc is involved in
so many aspects of cell growth and proliferation, inhibiting its
functions could cause serious side-effects in normal tissues.
However, Soucek and Evan [21], have shown that the systemic
expression of omomyc - the cDNA coding for a mutated form of the
b-HLH-LZ of c-Myc called Omomyc [22],[23], [24] – leads to
clearance of tumors in mouse models of lung and pancreatic islet
tumors without causing damage to normal tissues. These results
demonstrated, for the first time, that c-Myc is a valid therapeutic
target and that its systemic inhibition can provide a high
therapeutic index. The mode of action of c-Myc resides in the
repression of c-Myc activated transcription alone. This is achieved
through the competition between the Omomyc/Max complex
with the endogenous c-Myc/Max heterodimer for E-box sequenc-
es at activated core promoters. However, the expression of omomyc
does not activate c-Myc repressed transcription. This is explained
by the fact that the Omomyc can still interact with Miz1 at
repressed core promoters.
While Omomyc has provided invaluable insights to understand
and model the validity of targeting c-Myc as a therapeutic
approach and how a b-HLHLZ domain from the c-Myc/Max/
Mad can be used to inhibit c-Myc, it is not a therapeutic agent per
se. However a b-HLH-LZ that could spontaneously and auto-
nomously transduce (penetrate) inside cells, translocate to the
nuclei and inhibit c-Myc transcriptional activities would certainly
represent a considerable step towards the development of a cancer
therapeutic agent.
In this study, we show that the b-HLH-LZ domain of Max
(Max*) possesses the ability to transduce into HeLa cells,
translocate to the nucleus and interfere with the transcriptional
activities of c-Myc. We show that the treatment of HeLa cells with
Max* leads to the transcriptional repression of pro-proliferative
genes and the transcriptional activation of cell cycle inhibitors.
Accordingly, HeLa cells are observed to undergo a G1 arrest and
apoptosis when treated with Max*. A substantial reduction in the
metabolism of treated HeLa cells is also observed. In summary,
our study reveals that the b-HLH-LZ of Max is a bona fide PTD
with the ability to inhibit c-Myc in cancer cells. These findings are
of fundamental importance for the development therapeutic b-
HLH-LZ domains designed to inhibit c-Myc.
Results
Max* can efficiently transduce across HeLa cell
membranes by endocytosis
It has been recently shown that NeuroD, a b-HLH transcription
factor, can spontaneously transduce into cells, translocate into
their nuclei and elicit transcriptional regulation [25]. The peptide
sequence, RRMKANARERNRM, located in the basic region was
shown to be responsible for the transduction (micropinocytosis)
and the nuclear localisation of NeuroD. As shown in Figure 1, a
homologous sequence is located in the basic region of Max. This
region is also similar to a nuclear localization signal (NLS) located
at the C-terminus of Max [26]. These similarities prompted us to
test, by immunofluorescence and confocal microscopy, whether
the b-HLH-LZ of Max (Max*) could also behave as a PTD and
translocate into the nucleus of HeLa cells (Figure 2).
In order to discriminate between Max* and the endogenous
Max, a HA tag was fused to the end of the LZ of Max* to generate
the Max*HA construct. Since the conditions (antibody concen-
tration and laser power) were set to give no endogenous Max
background, the transduction phenomenon should be revealed by
both the a-Max (polyclonal) and a-HA. As shown in Figure 2A, a
20 minute incubation of HeLa cells with 10 mM of Max*HA led to
diffuse (cytoplasm and nucleus) and punctuated intracellular
labeling. As expected, the diffuse and punctuated immunofluores-
cence of the Max and HA antibodies are clearly colocalized. The
same diffuse and punctuated immunofluorescence is obtained
when HeLa cells are treated with Max* without the HA tag and
the latter is revealed with the monoclonal a-Max (vide infra). This
result indicates that the HA tag is not responsible for the
transduction and that it is dispensable for the discrimination of
endogenous Max and exogenous Max*. The cytoplasmic inclu-
sions (punctuated labeling) observed in Figure 2A resembled to
endosomal structures. These could originate from macropinocy-
tosis or receptor-mediated endocytic uptake. In order to unveil the
actual transduction mechanism, cells were treated and incubated
at 4uC to inhibit internalization. At this temperature, the
Figure 1. The b-HLH-LZ of Max has a putative NLS sequence and PTD in its basic region. Primary structure of the b-HLH-LZ of Max (Max*).
Also shown is the domain of NeuroD responsible for its transduction and nuclear localization and the Max NLS. Note the high content in basic side-
chains and the similarity between the sequences.
doi:10.1371/journal.pone.0032172.g001
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detectable signal in the cytoplasm and the nucleus (Figure 2B).
Since cellular uptake and/or translocation is affected by
temperature [27]. This result supports the notion that Max*HA
transduces through an active cellular uptake such as endocytosis.
To confirm that Max*HA transduces by endocytosis, HeLa cells
were simultaneously treated with Max*HA and Transferrin-
AF488,
a bona fide ligand of the clathrin-dependant endocytic pathway. As
displayed in Figure 3, Max*HA (Fig. 3A) and Transferrin-
AF488
(Fig. 3B) are colocalized (Fig. 3C) in similar and common
structures. Although partial, this co-localization further indicates
a clathrin-dependent uptake of Max*HA.
Clathrin-dependent endocytosis is dependent on Dynamin1
[28]. Dynamin1 is a GTPase implicated in the scission of the new
vesicles from the cytoplasmic membranes. To verify if Max* is
transduced by a Dynamin-dependent endocytosis, we transiently
transfected HeLa cells with a dominant negative and GTPase
defective Dynamin1 (K44A mutant) [29], [30] prior incubation
with Max* for 30 minutes. As one can observe in Figure 4, the
transient transfection of the dominant negative effectively inhibits
the endocytosis of Transferrin-
AF488 as well as Max*. Indeed, both
proteins are at the cell surface or in vesicles near the plasma
membrane. As stated above, this experiment also highlights the
ability of Max* to transduce into HeLa without the necessity of
the HA tag. In order to provide additional credence to the
dependence of the transduction of Max* on Dynamin1, we treated
cells with the Dynamin inhibitor, Dynasore [31], prior to
incubation with Max* (Figure 5). As can be seen, the endocytosis
of Max* is blocked by the Dynasore treatment. Taken together
these experiments demonstrate that Max* can transduce into
HeLa cells through a clathrin- and Dynamin-mediated endocytic
mechanism.
Time dependent cellular distribution and nuclear
accumulation
In order to follow the intracellular transport of Max*, HeLa
cells were incubated with Max* for 12 hours at 37uC. Cells were
then carefully washed and the immunofluorescence was subse-
quently monitored after 0, 18 and 36 hours (Figure 6A, B and C).
All the laser settings and concentrations were kept constant in
order to evaluate the relative distribution of the fluorescence. One
can see a gradual accumulation of a diffuse nuclear fluorescence
with time. Concomitantly, a decrease in the cytoplasmic diffused
and punctuated fluorescence is also observed. This is suggestive of
Figure 2. The b-HLH-LZ of Max directly transduces into HeLa cells. Confocal immunofluorescence photomicrographs of HeLa cells incubated
for 20 minutes with Max*-HA at 37uC A) and 4uC B). Detection with a-Max, a-HA tag and the merge are displayed from left to right respectively. A)
Note the punctuated (endosomes) and diffused labeling inside the cytoplasm and nucleus. B) At 4uC, internalization is inhibited and the fluorescence
is confined to the cell surface. Note the colocalization of the fluorescence of the a-Max and a-HA labeling. Scale bar=10 mm.
doi:10.1371/journal.pone.0032172.g002
Figure 3. The transduction of Max* colocalizes with the internalized Transferrin. Confocal photomicrographs of HeLa cells simultaneously
incubated with Max*HA and Transferrin-
AF488 for 30 minutes. A) Immumofluorescence labeling of Max*HA, B) Fluorescence of Transferrin-
AF488 and C)
Merge. Scale bar=10 mm.
doi:10.1371/journal.pone.0032172.g003
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However, the persistence of the punctuated fluorescence implies
that the endosomal escape is not total. These results indicate a
time dependent accumulation of Max* into the nuclei of HeLa
cells.
The treatment of HeLa cells with Max* leads to the
inhibition of c-Myc transcriptional activities
To validate the expected inhibitory effect of a Max* treatment
on c-Myc transcriptional activities in HeLa cells, we monitored the
mRNA levels of key target genes repressed and activated by c-Myc
by qPCR. As summarized in Figure 7A, a dose-dependent and
transient up-regulation of p21 (Figure 7B) and p27 is observed at
24 hours. At 48 hours, the transcription of Rb1 is also upregu-
lated. In accordance with our expectations, a dose-dependent
repression of CyclinD1 (Figure 7C) and CyclinB1 as well as cdc25a
(24 hours), CDK4 (48–72 hours) and CyclinE1 (72 hours) is
observed.
Cell cycle analysis and apoptosis of HeLa cells treated
with Max*
Given that an upregulation of p21, p27 and Rb1, coupled to a
downregulation of Cyclins B1, D1and E1 and CDK4 should,
classically, give rise to a G1 arrest, we investigated the effect of
Max* treatment on the cell cycle distribution of HeLa cells by
FACS. As shown in Figures 8A, B and C, the treatment of HeLa
cells with 50 mM Max* leads to a significant increase in the
population of cells in G0/G1 and a decrease in the population of
cells in the S phase. Concurrently, no significant accumulation of
cells in G2/M was detected (Figure 8D). However as shown in
Figure 8E, a significant percentage of cells are undergoing
apoptosis.
Inhibition of the proliferation of HeLa cells by Max*
treatment
The observed reduction of the population of HeLa cells in S
phase and the accumulation in G1 phase due to the treatment with
Max* should also lead to a reduction in proliferation, or in the
expansion of viable cells. To evaluate the impact of Max*
treatment on the proliferation of HeLa cells we used a colorimetric
WST-1 cell expansion assay. As shown in Figure 9, treatment with
increasing concentrations of Max* decreases cell expansion in a
dose-dependent manner. A 34.8% decrease in proliferation is
observed at 72 hours with a single treatment with 50 mM of Max*.
Discussion
In this work, we have demonstrated for the first time the ability
of the b-HLH-LZ domain of Max (Max*) to transduce into HeLa
cells by a Dynamin-dependent endocytic mechanism (Figures 2, 3,
4, and 5). Although not complete, we have found that Max* was
able to escape endosomes and to accumulate in the nucleus of
HeLa cells (Figure 6). Similar results have been obtained with
HCT116, F98, U118 and U87 cell lines (data not shown)
indicating that this property is not specific to HeLa cells. Although
we have not demonstrated which domains of Max* are responsible
for the transduction and nuclear localization, it is interesting to
note that Max* shares a sequence in its basic region which is
highly homologous to that of NeuroD (a b-HLH transcription
factor), also located in its basic region, which was demonstrated to
be responsible for its transduction and nuclear localization
(Figure 1). Hence, it is tempting to suggest that this sequence,
KRAHHNALERKRR, is also responsible for both activities.
Consistently, its high basic residue content (K and R) meets the
requirement for the existence of a PTD sequence [32]. Moreover,
a NLS in the C-terminus of Max with the following sequence
RKKLR has been identified [26]. This sequence is also highly
similar to the C-terminal part of the putative PTD/NLS sequence
identified in Max* (Figure 1). Work is underway in our laboratory
to identify the domains of Max* responsible for its internalization
and nuclear localization. Current and future efforts also aim to
improve these activities and optimize the endosomal escape.
We have also shown that the incubation of HeLa cells with
Max* considerably decreased cellular proliferation (Figure 9).
Accordingly, HeLa cells undergoing this treatment also showed a
significant accumulation in the G1 phase and a significant
Figure 4. The transfection of the defective Dynamin1 K44A
mutant blocks the endocytosis of Max* into HeLa cells. Confocal
photomicrographs of HeLa cells transfected or not with a vector
encoding for the dominant-negative mutant of dynamin1(K44A) and
incubated with Max* and AlexaFluor-488 transferrin for 20 minutes at
37uC (subsequent to a 30 minutes pre-incubation period at 4uC).
Immunofluorescence staining of Max* without A) and with B) the
transfection of the Dynamin1 (K44A) mutant. Fluorescence of Transfer-
rin-
AF488 without C) and with D) the transfection of the Dynamin1
(K44A) mutant. Scale bar=10 mm.
doi:10.1371/journal.pone.0032172.g004
Figure 5. The transduction of Max* in HeLa is blocked by
Dynasore. Confocal immunofluorescence photomicrographs of HeLa
cells incubated with Max* for 20 minutes at 37uC (subsequent to a
30 minutes pre-incubation period at 4uC) in the absence A) or presence
of B) 25 mM Dynasore. Scale bar=10 mm.
doi:10.1371/journal.pone.0032172.g005
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these phenotypic changes, we have shown by qPCR, that the
transduction of Max* activated the transcription of the cell cycle
inhibitors (p21 and p27) and repressed the transcription of CDK4
and Cyclin D1. Considering that the regulatory (up and down)
effects of c-Myc on transcription are usually 2–3 fold [13], [33],
the levels of activation (Figure 8B) and repression (Figure 8C)
obtained here are very significant and noteworthy.
The genes affected by the transduction of Max* are bona fide c-
Myc target genes and classically recognized to control the passage
through the first checkpoint of the cell cycle and the entry into the
S phase. Hence the activation p21 and p27 and the downregu-
lation of CDK4 and Cyclin D1 are expected to lead, as observed,
to an accumulation in the G1 phase and a decrease in the S phase.
Consequently, an accumulation in the G2/M phase should have
been observed. Although we observed such a trend, this apparent
accumulation in G2 was not found to be statistically significant.
On the other hand, the transduction of Max* into HeLa cells was
accompanied by a significant increase in the level of cells
undergoing apoptosis. This could explain, in part, the fact that
we do not detect an accumulation in G2/M. Moreover, we also
observed a downregulation of Cyclin B1, a key cyclin for the
passage through the second checkpoint and entry into the G2
phase.
The results presented here are highly important and worthy of
note in the context of c-Myc inhibition as a therapeutic tool.
Moreover, they represent a step forward in the development of a
therapeutic b-HLH-LZ. Indeed, whereas the systemic expression
of omomyc - the cDNA coding for a mutated form of the c-Myc b-
HLH-LZ [34] – provides an outstanding anti-tumor activity in
animal models [21], [35], unlike Max*, it is not directly
deliverable. Moreover, the mode of action of Omomyc in vitro
has been recently described and shown to rely mainly on the
inhibition of the transactivation of genes promoting proliferation
and growth. Indeed, as shown here for Max*, Savino et al. [24]
observed that Omomyc can repress the transactivation of
CyclinD1, CyclinB1 and Nucleolin by c-Myc (Figure 7). However,
Omomyc does not lead to the activation of Myc repressed genes as
observed for Max* here (Figure 7A and B). In fact, Omomyc can
repress the transcription of p21 [24]. This is due to the fact that
while Omomyc can heterodimerize with Max and compete with
the endogenous c-Myc/Max at activated promoters, the Omo-
myc/Max complex can still interact with Miz1 at repressed
promoters and sustain repression. However, since Max* does not
interact with Miz1 [14], its homodimeric state can compete with
the endogenous c-Myc/Max (and even Max*/c-Myc heterodimer)
and give rise to an activation of c-Myc repressed genes as observed
here.
Materials and Methods
HeLa cells were purchased from ATCC (American Type
Culture Collection, Manassas, VA, USA). DMEM Cell culture
media, serum, PBS (10X) and trypsin, were purchased from
Wisent (St-Bruno, QC, Canada). Monoclonal Mouse anti-Max
(H-2), anti-c-Myc (9E10), anti rat monoclonal c-Myc (3H603) and
anti-rat IgG1NAlexa FluorH 488, rabbit polyclonal anti-HA probe
(Y-11)NAlexa-FluorH-647 (far-red) and goat anti-rabbitNAlexa-
FluorH-488 (sc-2780) were obtained from SantaCruz Biotechnol-
ogy (Santa Cruz, CA, U.S.A.). Alexa-FluorH 488 (green) and
Alexa-FluorH-594 (red) goat anti-mouse antibodies were obtained
from Molecular Probes (Burlington, ON, Canada). Western
Lightning Chemiluminescence Reagent Plus was purchased from
PerkinElmer Life Sciences (Woodbridge, ON, Canada). Dynasore
hydrate (D7693) was obtained from Sigma-Aldrich.
Prokaryotic expression plasmids
The human Max b-HLH-LZ corresponding cDNA (P25912,
amino acids: 22–104) was first subcloned in the pET-3a expression
plasmid (Novagen) by polymerase chain reaction (PCR) using
pVZ1 p21max as template (kindly provided by R. N. Eisenman,
Fred Hutchinson Cancer Research Center, Seattle, WA) and
oligonucleotides containing 59-NdeI-and 39-BamHI restriction sites.
The plasmid pET3a and the PCR products were digested with the
corresponding restriction enzymes before purification on agarose
gel using QIAquick gel extraction Kit (Qiagen) and ligation using
T4 Ligase (NewEngland Biolabs, Pickering, ON, Canada). The
absence of a stop codon allowed for a 39-GSGC extension from
pET3a vector to obtain Max*-cys (name thereafter Max*).
For confocal microscopy, amino acids corresponding to the
hemagglutinin (HA) tag (YPYDVPDYA) sequence were intro-
duced at the C-terminus of Max*/pET3a DNA template by
QuikChange
TM Site-Directed Mutagenesis (Qiagen) using oligonucle-
otides (59)CGT GCA CTG GAG TAC CCA TAC GAT GTT CCA
GAT TAC GCT GGA TCC GGC and (39)GCC GGA TCC AGC
GTA ATC TGG AAC ATC GTA TGG GTA CTC CAG TGC
ACG. This clone (Max*-HA) was subjected to a final Quik-
Change
TM Site-Directed Mutagenesis to remove the last cystein using
(59)CCC ATA CGA TGT TCC AGA TTA CGC TTA AGG
ATC CAC GCG G and (39)CCG CGT GGA TCC TTA AGC
GTA ATC TGG AAC ATC GTA TGG G oligonucleotides,
thereby preventing unconventional protein oligomerization. Mod-
ifications were confirmed by DNA sequencing.
Protein expression and purification
BL21 (DE3) pLysS Escherichia coli (Stratagene) were transformed
with the b-HLH-LZ of Max* or Max*HA respectively on LB-agar
Figure 6. Accumulation of Max* in the nucleus of HeLa cells. Confocal immunofluorescence photomicrographs of HeLa cells incubated with
Max* for 12 hours, washed and chased for 0 hour (A) 18 hours (B) and 36 hours (C). Cells were fixed, permeabilized and immunolabeled with anti-
Max antibodies. Scale bar=10 mm.
doi:10.1371/journal.pone.0032172.g006
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grown at 37uC overnight. Using a single colony, a pre-culture was
inoculated in 2YT medium with fresh antibiotics and grown for an
additional 16 hours. 5 L of culture was then prepared using a 2%
dilution from the pre-culture. The cultures were allowed to grow
until turbidity reached 0.8 (D.O. at 595 nm) where protein
expression was induced with 0.6 mM of IPTG (Isopropyl-ß-D-
thiogalactopyranosid). After a growth period of four hours, cells
were harvested by centrifugation. Soluble protein extracts were
then purified by cation-exchange chromatography columns (GE
Healthcare) to isolate highly pure recombinant proteins as
previously described [36]. The fractions containing the Max* or
the Max*HA proteins were collected, desalted on HighTrap
desalting columns (GE Healthcare) using 0.05% H2ONTFA and
Figure 7. The treatment of HeLa cells with Max* induces cell cycle arrest and apoptosis. A) Representative cell cycle distribution
determined by flow cytometry (FACS) and propidium iodide (PI) labeling with (right) and without (left) treatment (50 mM, 72 hours) with Max*. B)
Histogram representation of the populations of HeLa cells in each phase as a function of treatment concentration. C) Relative level of apoptotic cells
as determined by sub-G1 events. N=3, * P,0.05, ** P,0.01 and *** P,0.0001.
doi:10.1371/journal.pone.0032172.g007
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v/v) acetonitrile. The
proteins were solubilized in PBS buffer, pH 7.5. Protein
concentrations were determined by the absorbance at 280 nm
using a molar extinction coefficient factor of 2980 mol
21 cm
21
and 7450 mol
21 cm
21 for Max* and Max*HA respectively.
Cell culture, transduction and transfection
HeLa cells (ATCC) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum at 37uC in a humidified atmosphere containing 5% CO2.
For confocal immunofluorescence microscopy, 35,000 HeLa cells
were seeded on 0.5 inch microscopy cover glass slips and grown
for 16 hours. Before treatment, cells were rinsed twice with
phosphate-buffered saline (PBS) (137 mM NaCl, 3.5 mM KCl,
10 mM sodium phosphate buffer, pH 7.4). Addition of fresh
media supplemented with Max* or Max*HA peptides (0–100 mM)
was followed by an incubation of 5 minutes to 72 hours. The
culture medium was refreshed every 48 hours. The transfection of
2 mg Dynamin1-K44A/pCB on 6-well plates seeded at 35,000
cells was done using FuGENE reagent (ROCHE). Transferrin
labeled with Alexa-FluorH-488 (50 ng/ml) and Dynasore (25–
80 mM, Sigma Aldrich) was added to culture media 30 to
60 minutes preceding Max* treatments.
Immunofluorescence
Hela cells were fixed in 3% paraformaldehyde/PBS pH 7.4, for
30 minutes, permeabilized with 0.1% Triton X–100 for 10 min-
utes, blocked with 10% goat serum for 30 minutes and incubated
Figure 8. Max* inhibits c-Myc transactivation and repression of transcription. A) Table summarizing qPCR measurement of the effect of a
treatment with Max* on a subset of repressed (second column, red) and activated (second column, green) c-Myc target genes in HeLa cells. Green
and red boxes indicate statistically significant dose-dependent activation and repression in transcription, respectively. Yellow boxes indicaten o
statistically significant trend. Orange boxes indicate non-statistically significant repression. Representative results are shown in B) and C) for activated
(p21) and repressed (Cyclin D1) genes by Max*, respectively.
doi:10.1371/journal.pone.0032172.g008
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washing with PBS/1% goat serum, Alexa Fluor–488, 594 or 647-
conjugated antibodies (Molecular Probes, Invitrogen) were added
for an extra hour at room temperature. Cover glass slips were
finally mounted on microscope slides using Permount
TM Mount-
ing medium (Fisher). The specimens were visualized using an
inverted confocal laser-scanning microscope (FV1000, Olympus)
equipped with a PlanApo 606/1.42 oil immersion objective
(Olympus). Olympus Fluoview software version 1.6 b was used for
image acquisition and analysis.
Proliferation and viable cell expansion assay (WST-1)
HeLa cells were incubated in 96-well plates over a period of
72 hours, increasing Max* concentration (0–50 mM). Addition of
10 ml/well of Premixed WST-1 Cell Proliferation Reagent
(Clontech) was added, and the cells were incubated for an
additional 90 minutes under the same conditions. Absorbance at
450 nm was measured in a multiwell plate reader.
Cell cycle analysis-Fluorescence-activated cell scanning
analysis (FACS)
Cells were analyzed with a FACScan cytometer (Becton
Dickinson, Mountain View, CA) equipped with a 15 mW argon
ion laser tuned at 488 nm forward and side scatter signals were
used to establish the live gate to exclude debris and cell clumps. A
minimum of 10,000 gated events per sample were acquired. The
fluorescence of propidium iodide (PI) was collected in red channel
on a linear scale detected with a 562–588 nm band pass filter. A
second live gate was set using the FL3-A and FL3-W parameters of
the doublet discrimination module (DDM), allowing single cell
measurements. Fluorescence intensity distribution was analyzed
with the CellQuest software. The percentages of cells in different
phases of cell cycle were calculated by ModFit software (Verity
Software House, Topsham, ME). The percentage of apoptotic
cells was determined by counting the number of events below G1
phase over the total number of events.
qPCR analysis
mRNA levels of our target genes in non-treated and treated cells
were reverse transcribed and measured using SYBR green-based
PCR. The qPCR experiments were carried out at the Laboratory
of Functional Genomics of the Universite ´ de Sherbrooke. Primers
for our gene subset were designed and validated using in-house
protocols. We used a relative quantification (DDCt) assay, where
the target transcript level is compared to the geometric mean of a
panel of 4 housekeeping genes. Data analysis was performed using
the qBase analysis package [37].
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